Animal models of focal epilepsy

Acta Neurologica Belgica

Volumn 99, Issue 4, 1999, Pages 222-225

  De Deyn, P P ^a   D'Hooge, R ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CLOBAZAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; NEUROTRANSMITTER; OXCARBAZEPINE; TIAGABINE; TOPIRAMATE; VIGABATRIN; ZONISAMIDE;

CONFERENCE PAPER; EPILEPTOGENESIS; FOCAL EPILEPSY; GABAERGIC TRANSMISSION; INTRACTABLE EPILEPSY; MEMBRANE CHANNEL; SPIKE;

EID: 0033374548     PISSN: 03009009     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (17)

1. BEN-ARI Y. Limbic seizures and brain damage produced by kainic acid: mechanisms and relevance to human temporal lobe epilepsy. Neuroscience, 1985, 14: 375-403.
2. BRAILOWSKY S., MENINI C., SILVA-BARRAT C., NAQUET R. Epileptogenic η-aminobutyric acid-withdrawal syndrome after chronic, intracortical infusion in baboons. Neurosci. Lett., 1987, 74: 75-80.
3. CAMPBELL A. M., HOLMES O. Bicuculline epileptogenesis in the rat. Brain Res., 1984, 323: 239-246.
4. DE DEYN P. P., D'HOOGE R., MARESCAU B., PEI Y. Q. Chemical models of epilepsy with some reference to their applicability in the development of anti-convulsants. Epilepsy Res., 1992, 12: 87-110.
5. DICHTER M. A. Modulation of inhibition and the transition to seizures. In: Mechanisms of Epileptogenesis. DICHTER M. A. (ed.). Plenum, New York, 1988, pp. 169-181.
6. DICHTER M. A. Basic mechanisms of epilepsy: targets for therapeutic intervention. Epilepsia, 1997, 38 (suppl. 9): S2-6.
7. DICHTER M. A., BRODIE M. J. New antiepileptic drugs. New Engl. J. Med., 1996, 334: 1583-1590.
8. FISHER R. S. Animal models of the epilepsies. Brain Res. Rev., 1989, 14: 245-278.
9. GODDARD G. V. Development of epileptic seizures through brain stimulation at low intensity. Nature, 1967, 214: 1020-1021.
10. HASHIMOTO H., SAKAKI T., HOSHIDA T., EGUCHI T., KUROKAWA S. I. The effect of lesionectomy and the perilesional GABAergic neuronal changes in alumina cream-induced focal motor epilepsy in cats. Neurol. Res., 1998, 20: 253-258.
11. LÖSCHER W., SCHMIDT D. Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res., 1988, 2: 145-181.
12. LOWENSTEIN D. H. Recent advances related to basic mechanisms of epileptogenesis. In: Rational Polypharmacy. LEPPIK I. E. (ed.). Elsevier, Amsterdam, 1996, pp. 45-60.
13. MCNAMARA J. O., BONHAUS D. W., SHIN C. Mechanisms of kindling: a speculative hypothesis. In: Mechanisms of Epileptogenesis. DICHTER M. A. (ed.). Plenum, New York, 1988, pp. 85-99.
14. MENINI C., MRAOVITCH S., CALANDO Y., DE LA SAYETTE V., SILVA-BARRAT C., BRAILOWSKY S., SEYLAZ J. Metabolic anatomy of the focal epilepsy produced by cessation of chronic intracortical GABA infusion in the rat. Neuroscience, 1991, 41: 607-615.
15. REMLER M. P., MARCUSSEN W. H. Systemic focal epileptogenesis. Epilepsia, 1986, 27: 35-42.
16. REMLER M. P., SIGVARDT K., MARCUSSEN W. H. Pharmacological response of systemically derived focal epileptic lesions. Epilepsia, 1986, 27: 671-677.
17. UPTON N. Mechanisms of action of new antiepileptic drugs: rational design and serendipitous findings. Trends Pharmacol. Sci., 1996, 15: 456-463.